The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...
City attorneys allege major Pharmacy Benefit Managers (PBMs) and insulin manufacturers are conspiring to artificially inflate ...
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
Axios Vitals on MSN8d
PBMs made more than $7B marking up specialty generics: FTCThe three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...
Given multiple recent news articles saying that pharmacies are struggling amid problems caused by pharmacy benefit managers (PBMs) , you might not be surprised by these examples. However ...
The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
President Donald Trump's effect on bank capital rules, crypto policy, antitrust scrutiny, and drug pricing are among key 2025 ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback